[Fetal toxoplasmosis. In utero treatment with pyrimethamine sulfamides].
The mothers of 52 cases of toxoplasmic fetopathy diagnosed in utero by fetal blood and/or amniotic fluid sampling were treated with the combination pyrimethamine-sulfadiazine (or sulfisoxazole) and by spiramycine. The infants were compared with 51 other infants with congenital toxoplasmosis whose mothers had received spiramycine alone. Patients of both groups received the same pyrimethamine-sulfadiazine and spiramycine treatment after birth. Parasitologic examination of the placenta was positive in 42 and 76.6% of patients, in group I and group II respectively. The newborns had specific IgM in 17.4 and 69.2% of cases respectively in both groups. These differences were significant. The mean specific IgG titer was significantly reduced at birth and 4 to 6 months of age in the first group. Patients in group I had more often subclinical infection than patients of the comparison group: 57% vs 33.3%. They had less often a high cerebro-spinal protein content during the first week. Prenatal treatment with pyrimethamine-sulfadrugs resulted in a less progressing infection at birth. However in cases with clinically patent toxoplasmosis, the frequency of overt localizations and their sequellae was not significantly altered. This might be related to a relatively late onset of the treatment. The pyrimethamine-sulfadrug combination given to mothers of proved infected fetuses can be rewarding. The indication might be extended to well-documented seroconverted mothers if, in the future, the acquired experience and necessary pharmacological studies bring the proof of its innocuousness.
Laboratoire de Sérologie, Institut de Puériculture, Paris.
J
J
Couvreur
P
P
Thulliez
F
F
Daffos
C
C
Aufrant
Y
Y
Bompard
A
A
Gesquière
G
G
Desmonts
D004359:Drug Therapy, Combination; D005260:Female; D005315:Fetal Diseases / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D011247:Pregnancy; D011295:Prenatal Care / Q000379:methods; D011739:Pyrimethamine / Q000008:administration & dosage / Q000627:therapeutic use*; D015572:Spiramycin / Q000627:therapeutic use; D013411:Sulfadiazine / Q000008:administration & dosage / Q000627:therapeutic use*; D014125:Toxoplasmosis, Congenital / Q000188:drug therapy*
D013411:Sulfadiazine; D015572:Spiramycin; D011739:Pyrimethamine
Foetopathie toxoplasmique. Traitement in utero par l'association pyriméthamine-sulfamides.